Group 1 - HNI closed at $47.92, with a 16.3% gain over the past four weeks, and analysts set a mean price target of $66, indicating a 37.7% upside potential [1] - The average price targets range from a low of $63 to a high of $70, with a standard deviation of $3.61, suggesting a 31.5% to 46.1% upside from the current price [2] - Analysts show strong agreement on HNI's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for HNI has increased by 7.1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - HNI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide for potential upside [13]

Group 1 - Vertical Aerospace Ltd. (EVTL) shares have increased by 64.9% over the past four weeks, closing at $5.69, with a mean price target of $10.30 indicating a potential upside of 81% [1] - The average price targets range from a low of $2 to a high of $15, with a standard deviation of $5.14, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 4.9% over the past month, indicating positive sentiment among analysts [12] - EVTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide guidance on the direction of price movement [13]

Group 1 - Aris Mining Corporation (ARMN) closed at $5.73, with a 5.3% gain over the past four weeks, and a mean price target of $8.29 indicating a 44.7% upside potential [1] - The average price targets range from a low of $7.02 to a high of $10.08, with a standard deviation of $1.40, suggesting a 22.5% increase at the lowest estimate and a 75.9% upside at the highest [2] - Analysts show strong agreement on ARMN's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ARMN's current year earnings has increased by 20.5% over the last 30 days, with two estimates moving higher and no negative revisions [12] - ARMN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Group 1 - Candel Therapeutics, Inc. (CADL) closed at $5.11, with an 11.8% gain over the past four weeks, and a mean price target of $21 suggests a 311% upside potential [1] - The average price targets range from a low of $15 to a high of $25, with a standard deviation of $4.90, indicating a variability in estimates; the lowest estimate suggests a 193.5% increase, while the highest indicates a 389.2% upside [2] - Analysts show strong agreement on CADL's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for CADL's current year earnings has increased by 17.5%, with one estimate moving higher and no negative revisions [12] - CADL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside in the near term [13]

Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]

Core Viewpoint - AtriCure (ATRC) shows potential for significant upside, with a mean price target of $49.89 indicating a 54.7% increase from its current price of $32.25 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.37, suggesting variability among analysts [2] - The lowest estimate of $40 indicates a 24% increase, while the highest estimate suggests an 86.1% surge to $60 [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AtriCure's earnings, with a positive trend in earnings estimate revisions indicating potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.1%, with four estimates moving higher and no negative revisions [12] - AtriCure holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research [10]

Shares of Intellia Therapeutics, Inc. (NTLA) have gained 14.9% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.08 indicates a potential upside of 408.6%.The mean estimate comprises 25 short-term price targets with a standard deviation of $26.66. While the lowest estimate of $9 indicates a 14.2% increase fro ...

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) shows significant upside potential with a mean price target of $76.43, indicating a 106.6% increase from the current price of $36.99 [1] Price Targets and Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $13.12, suggesting variability among analysts [2] - The lowest estimate of $55 indicates a 48.7% increase, while the highest estimate predicts a surge of 181.2% to $104 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with two estimates going higher and no negative revisions [12] - MLTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at $17.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.14 indicates a potential upside of 105.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 57.9% increase from the current pric ...

QuinStreet (QNST) closed the last trading session at $15.88, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.40 indicates a 78.8% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.90. While the lowest estimate of $19 indicates a 19.7% increase from the current price level, the most optimistic analyst expects ...